## **FRESENIUS MEDICAL**

ISIN: **DE0005785802** WKN: **578580** Asset Class: **Stock** 



Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

### Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	<b>2</b> 2	202	01
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	8,565,168,000		8,056,523,000		7,812,639,000	
Common stock capital		293,413,000		293,413,000		293,004,000
Fixed assets	25,364,640,000		27,697,591,000		26,553,919,000	
Equity capital of a company		14,826,535,000		15,449,179,000		13,979,037,000
Cash and cash equivalents	1,403,492,000		1,273,787,000		1,481,655,000	
Accrued liabilities		839,624,000		709,689,000		965,914,000
Other assets	-		-		-	
Current liabilities		6,111,590,000		6,467,314,000		7,257,634,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		12,991,683,000		13,837,621,000		13,129,887,000
Different income		-		-		-
Other liabilities		912,923,000		1,015,785,000		560,769,000
Total assets	33,929,808,000	33,929,808,000	35,754,114,000	35,754,114,000	34,366,558,000	34,366,558,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	119,845	128,044	122,909
Equity ratio	47.25%	47.29%	44.40%
Debt-equity ratio	111.63%	111.45%	125.22%

Others			
	2023	2022	2021
Tax Expense Rate	32.98%	28.19%	23.85%

# **FRESENIUS MEDICAL**

ISIN: <b>DE0005785802</b>	WKN:	578580	Asset Class:	Stock
---------------------------	------	--------	--------------	-------

### Income statement

	2023	2022	2021
Turnover	19,454,117,000	19,395,319,000	17,618,410,000
Net income	498,997,000	673,405,000	969,308,000
EBIT	1,236,724,000	1,435,794,000	1,764,011,000
Operating income before taxes	911,230,000	1,152,720,000	1,479,686,000
Cash Flow	2,628,801,000	2,167,379,000	2,489,498,000
Net interest income	-325,494,000	-283,074,000	-284,325,000
Research and development expenses	231,970,000	228,624,000	220,782,000
Income taxes	300,557,000	324,954,000	352,833,000
Result from investments in subsidaries, associates and other	121,785,000	66,559,000	92,175,000
Revenues per employee	162,327	151,474	143,345

### **Board of Directors**

Chairman of Supervisory Board	
Member of Supervisory Board	
	Member of Supervisory Board Member of Supervisory Board

## Members of Management Board

Helen Ping Giza	Chairman of Managing Board
Frank Maddux	Member of Executive Committee
Craig Cordola	Member of Executive Committee
Jörg Häring	Member of Executive Committee
M.D., Ph.D. Katarzyna Mazur-Hofsaess	Member of Executive Committee
Martin Fischer	Member of Executive Committee